Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Thrombotic eosinophilic vasculitis
Clinical and Experimental Dermatology, 06/16/09
Nakajima H et al. - Eosinophilic vasculitis is characterized by pruritic erythema, papules and angio-oedema. The authors report a case of thrombotic eosinophilic vasculitis with leg oedema and widespread purpura, which resulted in extensive gangrene. Corticosteroids and anticoagulants relieved the symptoms; however, deep ulcers remained after the removal of gangrene. An attempt to decrease corticosteroid dose caused a recurrence of purpura.
Related Articles
Resolution of anti-neutrophil cytoplasmic antibody-associated vasculitis after resection of gastric cancer
Modern Rheumatology, 10/19/09
Relevance Score: 46%
European League Against Rheumatism/European Vasculitis Study Group recommendations for the management of vasculitis
Current Opinion in Rheumatology, 10/16/09
Relevance Score: 46%
Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9
Journal of Rheumatology, 10/20/09
Relevance Score: 45%
Cutaneous vasculitis induced by TNF inhibitors: a report of three cases
Modern Rheumatology, 10/16/09
Relevance Score: 44%
Analysis of T-cell receptor usage in myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis
Clinical and Experimental Nephrology, 10/09/09
Relevance Score: 44%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam
Pharmacoepidemiology and Drug Safety, 12/09/09
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


